JP Morgan Chase
ORIC icon

JP Morgan Chase’s Oric Pharmaceuticals ORIC Stock Holding History

JP Morgan Chase’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Sell
308,268
-15,316
-5% -$139K ﹤0.01% 3851
2026
Q1 		$3.94M Sell
323,584
-91,202
-22% -$1.04M ﹤0.01% 3544
2025
Q4 		$3.39M Sell
414,786
-813,742
-66% -$9.37M ﹤0.01% 3668
2025
Q3 		$14.7M Sell
1,228,528
-106,920
-8% -$1.12M ﹤0.01% 2360
2025
Q2 		$13.6M Buy
1,335,448
+1,299,799
+3,646% +$8.73M ﹤0.01% 2283
2025
Q1 		$199K Buy
35,649
+1,913
+6% +$16.7K ﹤0.01% 5240
2024
Q4 		$272K Sell
33,736
-1,515
-4% -$13.9K ﹤0.01% 5343
2024
Q3 		$361K Buy
35,251
+1,279
+4% +$12.6K ﹤0.01% 5105
2024
Q2 		$240K Buy
33,972
+2,171
+7% +$19.4K ﹤0.01% 5073
2024
Q1 		$437K Sell
31,801
-6,374
-17% -$75.7K ﹤0.01% 4878
2023
Q4 		$351K Buy
38,175
+11,405
+43% +$82.5K ﹤0.01% 5012
2023
Q3 		$162K Sell
26,770
-4,254
-14% -$34.9K ﹤0.01% 5193
2023
Q2 		$241K Buy
31,024
+29,864
+2,574% +$170K ﹤0.01% 4969
2023
Q1 		$6K Buy
1,160
+400
+53% +$2.09K ﹤0.01% 6216
2022
Q4 		$4K Sell
760
-12,984
-94% -$43.8K ﹤0.01% 6210
2022
Q3 		$44K Buy
13,744
+7,822
+132% +$31.3K ﹤0.01% 5592
2022
Q2 		$27K Sell
5,922
-13,732
-70% -$54.8K ﹤0.01% 5830
2022
Q1 		$105K Buy
19,654
+3,794
+24% +$34.2K ﹤0.01% 5482
2021
Q4 		$233K Sell
15,860
-6,080
-28% -$94.8K ﹤0.01% 5269
2021
Q3 		$459K Buy
21,940
+5,505
+33% +$112K ﹤0.01% 4782
2021
Q2 		$291K Buy
16,435
+4,761
+41% +$104K ﹤0.01% 5033
2021
Q1 		$286K Buy
11,674
+1,723
+17% +$54.4K ﹤0.01% 4997
2020
Q4 		$337K Buy
9,951
+6,705
+207% +$192K ﹤0.01% 4587
2020
Q3 		$75K Sell
3,246
-2,971
-48% -$70.7K ﹤0.01% 4822
2020
Q2 		$210K Buy
+6,217
New +$198K ﹤0.01% 4235

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's ORIC Position: Q2 2026 in Review

JP Morgan Chase reduced its Oric Pharmaceuticals (ORIC) stake by 4.7% in Q2 2026, selling an estimated $139K and leaving 308,268 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3851.

JP Morgan Chase first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $14.7M in Q3 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • JP Morgan Chase held 308,268 shares of Oric Pharmaceuticals worth $3.13M as of Q2 2026.
  • JP Morgan Chase sold 15,316 Oric Pharmaceuticals shares in Q2 2026, an estimated $139K.
  • Oric Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3851 holding.
  • JP Morgan Chase first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Oric Pharmaceuticals position peaked at $14.7M in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.